A Questionnaire-based Survey to Assess Patient Satisfaction, Ease-of-learning, Ease-of-use, Injection Site Pain and Overall Patient Satisfaction of the Follitropin-alpha (Gonal-f) Filled-by-mass (FbM) Prefilled Pen Compared with Other Systems Of...

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2012 Nov 22

PMID 23167906

Citations 3

Authors

Takafumi Utsunomiya

Atsushi Tanaka

Kenichi Tatsumi

Diego Ezcurra

Affiliations

Soon will be listed here.

Abstract

Background: Gonadotrophins are used routinely for follicular stimulation during ovarian induction and assisted reproduction techniques. Developments in recombinant follicle-stimulating hormone preparations and their injection devices have improved patient quality of life by enabling patients to self-administer treatment at home. The objective of this study was to investigate patient experiences of learning to use and overall satisfaction with the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen.

Methods: This questionnaire-based survey study was conducted in 23 fertility centres in Japan over a period of 14 months. Patients who were receiving fertility treatment with the follitropin-alpha (FbM) prefilled pen were asked to complete a questionnaire to assess their satisfaction, ease of learning and use, and injection site pain following treatment.

Results: A total of 663 women participated in the study. The majority of patients found the instructions for administering follitropin-alpha with the prefilled pen easy to understand (83.0%; n = 546/658) and patients found that a hands-on demonstration by a nurse or doctor was the most useful tool for learning to use the follitropin-alpha (FbM) prefilled pen (80.0%; n = 497/621). Forty-eight percent (n = 318) of patients in the study had previous experience with different types of fertility medications and the majority of these patients found the follitropin-alpha (FbM) prefilled pen easier to use (75.1%; n = 232/309) and less painful (89.0%; n = 347/390) than their previous medication. The majority (80.2%; n = 521/650) of patients reported overall satisfaction with the follitropin-alpha (FbM) prefilled pen.

Conclusions: The follitropin-alpha (FbM) prefilled pen is an easy-to-use injection device according to this questionnaire-based survey. Patients who had experience of different types of fertility medication preferred the follitropin-alpha (FbM) prefilled pen to other injection devices.

Citing Articles

Analysis of Nurse and Patient Preferences for Pre-Filled Pen Devices for Self-Injection of Highly Purified Human Menopausal Gonadotropin (HP-hMG, MENOPUR).

De Mesmaeker G, Calles B, Smith J Patient Prefer Adherence. 2023; 17:1281-1292.

PMID: 37220565 PMC: 10200119. DOI: 10.2147/PPA.S385247.

Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets.

Zitoun P, Parikh J, Nijs M, Zhang W, Levy-Toledano R, Tang B Int J Womens Health. 2019; 11:11-21.

PMID: 30662286 PMC: 6327888. DOI: 10.2147/IJWH.S175775.

Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.

Strowitzki T, Kuczynski W, Mueller A, Bias P Reprod Biol Endocrinol. 2016; 14(1):31.

PMID: 27287439 PMC: 4902897. DOI: 10.1186/s12958-016-0164-y.

References

Craenmehr E, Bontje P, Hoomans E, Voortman G, Mannaerts B . Follitropin-beta administered by pen device has superior local tolerance compared with follitropin-alpha administered by conventional syringe. Reprod Biomed Online. 2003; 3(3):185-189. DOI: 10.1016/s1472-6483(10)62033-0. View

Somkuti S, Schertz J, Moore M, Ferrande L, Kelly E . Patient experience with follitropin alfa prefilled pen versus previously used injectable gonadotropins for ovulation induction in oligoanovulatory women. Curr Med Res Opin. 2006; 22(10):1981-96. DOI: 10.1185/030079906X132604. View

Brunton S . Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008; 10(4):247-56. DOI: 10.1089/dia.2008.0287. View

Kadiri A, Chraibi A, Marouan F, Ababou M, el Guermai N, Wadjinny A . Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998; 41(1):15-23. DOI: 10.1016/s0168-8227(98)00055-2. View

Platteau P, Laurent E, Albano C, Osmanagaoglu K, Vernaeve V, Tournaye H . An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod. 2003; 18(6):1200-4. DOI: 10.1093/humrep/deg234. View

Hovatta O, McVeigh E, Lass A, Homburg R . A large Northern European observational study of follitropin alpha filled-by-mass pre-filled pen. Reprod Biomed Online. 2009; 18(4):502-8. DOI: 10.1016/s1472-6483(10)60126-5. View

Sucic M, Galic E, Cabrijan T, Ivandic A, Petrusic A, Wyatt J . Patient acceptance and reliability of new Humulin/Humalog 3.0 ml prefilled insulin pen in ten Croatian diabetes centres. Med Sci Monit. 2002; 8(3):PI21-6. View

Chen L, Quan S, Li H, Yang X, Chen S, Zhang X . [Clinical application of prefilled pen and conventional syringe during controlled ovarian stimulation for in vitro fertilization]. Nan Fang Yi Ke Da Xue Xue Bao. 2009; 29(1):100-4. View

Christianson M, Barker M, Schouweiler C, Lindheim S . A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotropins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles. Curr Med Res Opin. 2007; 23(4):865-70. DOI: 10.1185/030079907x178784. View

10.

Oehninger S . Ovulation induction in IVF. Minerva Ginecol. 2011; 63(2):137-56. View

11.

Mahato R, Narang A, Thoma L, Miller D . Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003; 20(2-3):153-214. DOI: 10.1615/critrevtherdrugcarriersyst.v20.i23.30. View

12.

Porter R, Kissel C, Saunders H, Keck C . Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. Curr Med Res Opin. 2008; 24(3):727-35. DOI: 10.1185/030079908X273291. View

13.

Alviggi C, Revelli A, Anserini P, Ranieri A, Fedele L, Strina I . A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular.... Reprod Biol Endocrinol. 2007; 5:45. PMC: 2216030. DOI: 10.1186/1477-7827-5-45. View

14.

Bohannon N . Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med. 1999; 106(5):57-8, 61-4, 68. DOI: 10.3810/pgm.1999.10.15.751. View

15.

Sedbon E, Wainer R, Perves C . Quality of life of patients undergoing ovarian stimulation with injectable drugs in relation to medical practice in France. Reprod Biomed Online. 2006; 12(3):298-303. DOI: 10.1016/s1472-6483(10)61001-2. View

16.

Pang S . A pen injection device for self-administration of recombinant follicle-stimulating hormone for fertility treatments. Expert Rev Med Devices. 2005; 2(1):27-32. DOI: 10.1586/17434440.2.1.27. View

17.

Oehninger S, Hodgen G . Induction of ovulation for assisted reproduction programmes. Baillieres Clin Obstet Gynaecol. 1990; 4(3):541-73. DOI: 10.1016/s0950-3552(05)80310-4. View

18.

Hanestad B, Albrektsen G . Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Diabet Med. 1991; 8(8):759-64. DOI: 10.1111/j.1464-5491.1991.tb01696.x. View

19.

Pang S, Kaplan B, Karande V, Westphal L, Scott R, Givens C . Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod Biomed Online. 2003; 7(3):319-26. DOI: 10.1016/s1472-6483(10)61871-8. View

20.

Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V . Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 2006; 6:5. PMC: 1618831. DOI: 10.1186/1472-6823-6-5. View